Publications by authors named "Cherie Perez"
Article Synopsis
- Men with low-risk prostate cancer are increasingly choosing active surveillance (AS) instead of immediate treatment, but many later switch to active treatment.
- A multi-institutional study analyzed genetic data from over 5,000 prostate cancer patients who opted for AS to identify genetic factors that might predict those likely to switch to treatment.
- The study found 18 genetic variants related to the decision to change treatment and established a link between certain genetic risk scores and the likelihood of converting from AS to active treatment, suggesting that genetics could personalize monitoring and treatment decisions for these patients.
Background: Because neither continuous nor intermittent hormonal therapy is curative, we designed a clinical model to screen new drugs for additive or synergistic effects with hormonal therapy and used IM862, a naturally occurring dipeptide with antiangiogenic and immunomodulatory properties, to test it.
Methods: Patients with prostate cancer who had rising PSA levels after radical prostatectomy and/or radiation therapy were given combined androgen ablation for 3 months. After 2 months' treatment, patients were randomly assigned in a double-blind fashion to receive intranasal IM862 or placebo daily.
Fluoropyrimidines are known to have modest activity in the treatment of metastatic renal cell carcinoma (RCC). Capecitabine is an orally administered prodrug that is converted to fluorouracil and is of potential use in the treatment of this disease. We conducted a Phase II clinical trial of capecitabine administered as a single agent to patients with metastatic RCC.
View Article and Find Full Text PDFPurpose: To study the platelet-derived growth factor receptor (PDGFR) inhibitor imatinib mesylate in androgen-independent prostate cancer (AIPC), alone and in combination with docetaxel, we designed a modular phase I trial. Our goals were to (1) evaluate the toxicity and maximum-tolerated dose of docetaxel with imatinib, and (2) evaluate the decline of prostate-specific antigen (PSA) induced by imatinib alone, and imatinib and docetaxel.
Patients And Methods: Twenty-eight men with AIPC and bone metastases were enrolled to receive imatinib 600 mg daily lead-in for 30 days, then imatinib 600 mg daily and one of six possible doses of docetaxel weekly for 4 weeks every 6 weeks.
Purpose: To determine the dose-limiting toxicity and maximum-tolerated dose of the proteasome inhibitor bortezomib administered intravenously weekly for 4 every 5 weeks; to determine the bortezomib pharmacokinetics and pharmacodynamics using plasma levels and an assay for 20S proteasome inhibition (PI) in whole blood; to correlate toxicity with bortezomib dose and degree of 20S PI; and to conduct a preliminary determination of the antitumor activity of bortezomib in patients with androgen independent prostate cancer (AIPCa).
Patients And Methods: Fifty-three patients (48 with AIPCa) received 128 cycles of bortezomib in doses ranging from 0.13 to 2.
Clinical aromatherapy. Part I: An introduction into nursing practice.
Clin J Oncol Nurs
December 2003
Purpose/objectives: To review standard and investigational treatments in advanced renal cell carcinoma, with a focus on thalidomide.
Data Sources: Published articles, conference proceedings, treatment guidelines, and textbooks.
Data Synthesis: The prognosis for advanced renal cell carcinoma when treated with standard regimens is poor; therefore, new treatments are needed.
Irofulven, a novel inhibitor of DNA synthesis, in metastatic renal cell cancer.
Invest New Drugs
November 2002
Irofulven (6-Hydroxymethylacylfulvene, MGI-114) is the first of a new class of anticancer compounds the acylfulvenes which are derived from the natural product, illudin S. Irofulven is a potent anticancer agent with activity against a broad range of human tumors in vitro and in vivo. Irofulven covalently binds to DNA, inhibits DNA synthesis and induces apoptosis.
View Article and Find Full Text PDFBackground: The highly vascular nature of renal cell carcinoma (RCC) suggests that angiogenesis inhibition may be therapeutic for patients with this disease. Thalidomide inhibits basic fibroblast growth factor and vascular endothelial growth factor (VEGF)-induced angiogenesis.
Methods: In a pilot study, we evaluated the safety and efficacy of escalating doses of thalidomide in patients with progressive metastatic RCC (mRCC), measurable disease, and good organ function.